● pepmg Research Desk · Peer-reviewed evidence review
What the research says about cerebrolysin
A neutral summary of the peer-reviewed literature on cerebrolysin, a porcine-brain-derived peptide preparation studied in stroke and dementia trials with conflicting results. Research use only.
Conflicting evidence — Studies disagree; the picture is unsettled. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pig brain tissue, marketed as a neuroprotective agent and studied in many randomized trials and meta-analyses, mostly for stroke and dementia [1][2].
- The evidence conflicts: a Cochrane review of stroke trials found no demonstrated clinical benefit and reported an increase in non-fatal serious adverse events (risk ratio about 2.47), while separate meta-analyses in Alzheimer's and vascular dementia reported cognitive benefits graded as very-low-quality [1][3][4].
- Several reviews note that many cerebrolysin trials were funded or supported by its manufacturer, a factor Cochrane authors flagged when appraising the evidence [1][3].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What cerebrolysin is
Cerebrolysin is described in the literature as a mixture of low-molecular-weight peptides and free amino acids derived from purified pig (porcine) brain tissue, said to have neurotrophic and neuroprotective properties [1]. It is given as a series of intravenous or intramuscular infusions and is widely used for stroke and dementia in Russia, China, Eastern Europe, and other regions, though it is not approved in many Western countries [1][4].
Material sold by third-party research-chemical vendors is not a regulated medicine and is offered for laboratory and research use only. This page summarizes the published trials.
What the human research has measured
Conflicting evidenceIn acute ischaemic stroke, a Cochrane systematic review (six randomized trials, 1501 participants) found that the available evidence did not demonstrate clinical benefit of cerebrolysin: there was no difference in all-cause death, and the review reported an increase in the number of people with non-fatal serious adverse events (risk ratio 2.47, 95% CI 1.09 to 5.58) [1]. The review authors noted that the manufacturer had supported several of the included trials [1]. More recent work points the other way: a 2026 meta-analysis of three observational studies reported better functional outcomes when cerebrolysin was added to mechanical thrombectomy (risk ratio 1.56, 95% CI 1.25 to 1.93), while cautioning that the data came only from small observational studies [10], and a 2025 randomized pilot in post-stroke aphasia reported greater language recovery with cerebrolysin plus speech therapy than with speech therapy alone [8].
In dementia, results are similarly mixed. A Cochrane review in vascular dementia (six trials, 597 participants) reported a beneficial effect on cognition (standardized mean difference 0.36, 95% CI 0.13 to 0.58) but graded the evidence as very-low quality, noting high risk of bias and that any benefit "may be too small to be clinically meaningful" [4]. A meta-analysis in mild-to-moderate Alzheimer's disease reported an advantage over placebo for global clinical change (odds ratio 3.32) [3], and a meta-analysis in traumatic brain injury pooling ten studies (8749 patients) reported improvements in coma and outcome scores while finding no effect on mortality or length of stay [5].
What the trials report on safety and adverse events
Conflicting evidenceSafety findings also differ by source. A manufacturer-associated safety review reported that adverse reactions were generally mild and transient, most commonly vertigo, agitation, and feeling hot, with an incidence similar to placebo in the trials analyzed [9]. The vascular-dementia and Alzheimer's meta-analyses likewise reported adverse-event rates comparable to placebo [4][3].
The Cochrane stroke review is the notable exception: while total serious adverse events did not differ significantly, it reported a statistically significant increase in non-fatal serious adverse events with cerebrolysin (risk ratio 2.47, 95% CI 1.09 to 5.58) [1]. Separately, a case report described a life-threatening anaphylactic reaction in an elderly stroke patient after intravenous cerebrolysin, a rare but documented event [7].
These are measured rates and reports within specific study populations, not a safety guarantee and not a prediction for any individual. This is not medical advice; consult a qualified professional and read the trials directly.
How strong is the evidence
The evidence is characterized as conflicting: high-quality Cochrane syntheses in stroke found no clear benefit and a possible increase in non-fatal serious adverse events, while other meta-analyses and newer trials in dementia, traumatic brain injury, and thrombectomy-adjunct settings report benefits, often graded low-quality and frequently from manufacturer-supported studies [1][3][4][5]. "Conflicting" describes the state of the published literature, in which well-designed reviews reach opposing conclusions, and it is not a verdict for or against the compound.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 9
- Cerebrolysin for acute ischaemic stroke (Cochrane review).
- Cerebrolysin for acute ischaemic stroke (Cochrane review, earlier version).
- Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
- Cerebrolysin for vascular dementia (Cochrane review).
- Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis.
- Life-Threatening Anaphylaxis due to Cerebrolysin.
- Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study.
- Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials.
- Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.